Efficacy and safety of batroxobin in patients with acute ischemic stroke: A multicenter retrospective analysis.
acute ischemic stroke
batroxobin
functional outcomes
stroke recurrence
Journal
CNS neuroscience & therapeutics
ISSN: 1755-5949
Titre abrégé: CNS Neurosci Ther
Pays: England
ID NLM: 101473265
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
18
06
2024
received:
04
01
2024
accepted:
13
07
2024
medline:
4
8
2024
pubmed:
4
8
2024
entrez:
4
8
2024
Statut:
ppublish
Résumé
The objective of this study was to evaluate the effectiveness of batroxobin in improving functional outcomes and reducing stroke recurrence among patients with acute ischemic stroke beyond the therapeutic time window for thrombolytic therapy. This multicenter, retrospective study enrolled 492 patients with acute moderate-to-severe ischemic stroke within 24 h. 238 patients were given standard (basic) therapy. On the basis of standard treatment, 254 patients received an initial intravenous infusion of batroxobin 10 U on day 1, followed by subsequent infusions of batroxobin 5 U on the 3rd and 5th days, respectively. In the batroxobin group, 8.3% of patients experienced recurrence stroke, compared to 17.2% in the control group (HR, 0.433; 95% CI, 0.248 to 0.757; p = 0.003). Furthermore, intravenous batroxobin significantly improved the distribution of 90-120 day disability. Moderate-to-severe bleeding events were reported in three patients (1.2%) in the batroxobin group and one patient (0.4%) in the control group (p = 0.369). Among patients with acute moderate-to-severe ischemic stroke beyond the time window for thrombolytic therapy, treatment with intravenous batroxobin had a lower risk of stroke recurrence and a better recovery of function outcome without increasing bleeding events. Prospective studies are needed to further confirm.
Substances chimiques
Batroxobin
EC 3.4.21.-
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14877Subventions
Organisme : Plan for High-level Talent Introduction
ID : 2000055
Organisme : Chongqing Postdoctoral Science Foundation
ID : CSTB2022NSCQ-BHX0634
Informations de copyright
© 2024 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.
Références
GBD 2017 DALYs and HALE Collaborators Global, Regional, and National Disability‐Adjusted Life‐Years (DALYs) for 359 Diseases and Injuries and Healthy Life Expectancy (HALE) for 195 Countries and Territories, 1990–2017: a Systematic Analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859–1922. doi:10.1016/s0140-6736(18)32335-3
Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS Rt‐PA stroke trials. Lancet (London, England). 2004;363(9411):768‐774. doi:10.1016/s0140-6736(04)15692-4
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early Management of Patients with Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344‐e418. doi:10.1161/str.0000000000000211
Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large‐vessel ischaemic stroke: a meta‐analysis of individual patient data from five randomised trials. Lancet (London, England). 2016;387(10029):1723‐1731. doi:10.1016/s0140-6736(16)00163-x
Jovin TG, Nogueira RG, Lansberg MG, et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta‐analysis. Lancet (London, England). 2022;399(10321):249‐258. doi:10.1016/s0140-6736(21)01341-6
Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317‐1329. doi:10.1056/NEJMoa0804656
Wang X, Ouyang M, Yang J, Song L, Yang M, Anderson CS. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2021;10(10):Cd000024. doi:10.1002/14651858.CD000024.pub5
Ní Chróinín D, Asplund K, Åsberg S, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta‐analysis of observational studies and randomized trials. Stroke. 2013;44(2):448‐456. doi:10.1161/strokeaha.112.668277
Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32(11):1032‐1040. doi:10.1038/hr.2009.139
Flach C, Muruet W, Wolfe CDA, Bhalla A, Douiri A. Risk and secondary prevention of stroke recurrence: a population‐base cohort study. Stroke. 2020;51(8):2435‐2444. doi:10.1161/strokeaha.120.028992
Ding JY, Pan LQ, Hu YY, et al. Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: a real‐world experience. CNS Neurosci Ther. 2019;25(5):638‐646. doi:10.1111/cns.13093
Zhang Z, Bao X, Li D. Batroxobin inhibits astrocyte activation following nigrostriatal pathway injury. Neural Regen Res. 2021;16(4):721‐726. doi:10.4103/1673-5374.295343
Yitao H, Kefu M, Bingshan T, et al. Effects of batroxobin with continuous transcranial doppler monitoring in patients with acute cerebral stroke: a randomized controlled trial. Echocardiography (Mount Kisco, NY). 2014;31(10):1283‐1292. doi:10.1111/echo.12559
Gusev EI, Skvortsova VI, Suslina ZA, et al. Batroxobin in patients with ischemic stroke in the carotid system (the multicenter study). Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(8):31‐34.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673‐682. doi:10.1056/nejm199309023291001
Hao Z, Liu M, Counsell C, Wardlaw JM, Lin S, Zhao X. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2012;3(3):Cd000091. doi:10.1002/14651858.CD000091.pub2
Lan D, Song S, Liu Y, Jiao B, Meng R. Use of Batroxobin in central and peripheral ischemic vascular diseases: a systematic review. Front Neurol. 2021;12:716778. doi:10.3389/fneur.2021.716778
Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke treatment with ancrod trial. JAMA. 2000;283(18):2395‐2403. doi:10.1001/jama.283.18.2395
Reassessment of defibrase in treatment of acute cerebral infarction: a multicenter, randomized, double‐blind, placebo‐controlled trial. Chin Med Sci J. 2005;20(3):151‐158.
Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM. Intravenous ancrod for acute ischaemic stroke in the European stroke treatment with ancrod trial: a randomised controlled trial. Lancet (London, England). 2006;368(9550):1871–1878. doi:10.1016/s0140-6736(06)69776-6
Levy DE, del Zoppo GJ, Demaerschalk BM, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke. 2009;40(12):3796‐3803. doi:10.1161/strokeaha.109.565119
Xu G, Liu X, Zhu W, Yin Q, Zhang R, Fan X. Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis. 2007;18(2):193‐197. doi:10.1097/MBC.0b013e328040c0f2
Rothwell PM, Howard SC, Power DA, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35(10):2300‐2305. doi:10.1161/01.STR.0000141701.36371.d1
Behar S. Lowering fibrinogen levels: clinical update. BIP study group. Bezafibrate infarction prevention. Blood Coagul Fibrinolysis. 1999;10(Suppl 1):S41‐S43.
Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese intracranial atherosclerosis (CICAS) study. Stroke. 2014;45(3):663‐669. doi:10.1161/strokeaha.113.003508
Pan Y, Chen W, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta‐analysis. Circulation. 2017;135(1):21‐33. doi:10.1161/circulationaha.116.024913